建发国际集团(01908)再涨近4%，截至发稿，涨3.8%，报16.11港元，成交额3757.86万港元。 该行预计，受高于预期的存货减值及投资物业冲销拖累，建发国际集团去年核心利润将按年减22%，虽 然短期盈利压力似乎主要体现在年初至今的业绩表现不佳，但仍对其前景持建设性看法。其持续的利润 率复苏、新鲜的土地储备及在豪宅项目的强大专业能力，将使其在减值减少及利润率持续改善的驱动 下，在2026年实现"V型"盈利反弹。 消息面上，汇丰环球研究发布研报指出，建发国际集团目前正面临低迷住宅市场及去年房价大幅修正带 来的盈利压力。在市场情绪疲软及公司上周五(1月23日)完成管理层交接的背景下，该公司可能在2025 年采取激进的减值确认措施，以调整盈利预测。该行将公司2025至2027年的合约销售额、营收预测分别 下调22%至28%及1%至15%；预测毛利率上调0.2至0.5个百分点；核心利润预估分别下调31%、20%、 19%。 ...

Core Viewpoint - Citigroup reports that WuXi AppTec's co-CEO Chen Minzhang provided insights at a U.S. healthcare conference, indicating that the company expects its organic growth in 2026 to be at least on par with 2025, with a projected annual growth rate of 16% and a continuous business growth rate of 21.4% [1] Group 1: Financial Outlook - The CFO anticipates improvements in profit margins due to ongoing optimization of manufacturing processes, increased capacity utilization, and operational efficiency, along with benefits from divesting certain business segments [1] - WuXi AppTec's TIDES (oligonucleotide and peptide) business is expected to see significant growth, with management projecting a more than 90% year-on-year increase in TIDES revenue for 2025 [1] Group 2: Capacity Expansion and Market Position - The company completed an expansion of solid-phase peptide capacity to 10,000 liters in Q3 2025 and plans further expansion in 2026 [1] - As of Q3 2025, WuXi AppTec holds a 16% market share in global clinical-stage innovative drug projects related to GLP-1, with 24 GLP-1 projects currently in progress [1] Group 3: Investment Rating - Citigroup maintains a "Buy" rating for WuXi AppTec, setting a target price of HKD 142, citing the company's strong market leadership in core business areas [1]

Core Viewpoint - The report from Shenwan Hongyuan maintains revenue projections for New Oriental-S (09901) for FY26-FY28 at $5.38 billion, $5.98 billion, and $6.73 billion, respectively, with expectations of profit margin pressure easing as the overseas study business stabilizes [1] Revenue Projections - Shenwan Hongyuan forecasts New Oriental's 2QFY26 revenue to be $1.165 billion, representing a year-on-year growth of 12.2% [2] - The education business (including cultural tourism) is expected to generate $957 million, up 11% year-on-year, while other businesses (mainly Dongfang Zhenxuan) are projected to earn $208 million, reflecting an 18% increase [2] Overseas Study Business - The overseas examination training and consulting business is anticipated to generate $242 million in 2QFY26, a decline of 3% year-on-year, with a slowdown of 33.3 percentage points compared to the same period last year [3] - The company is adjusting its high-end one-on-one training model to a one-to-many format to lower class prices and is expanding its youth overseas examination training services to enhance growth resilience [3] New Business Growth - New business revenue (K9 competency training + learning machine business) is expected to grow by 21% year-on-year to $364 million in 2QFY26, driven by high growth in non-subject competency services [4] - The number of teaching centers is projected to increase to 1,368, a 20% year-on-year growth, with a slight slowdown of 3.7 percentage points compared to 1QFY26 [4] Operating Profit Margin Improvement - Despite the slowdown in high-margin overseas study business, the increase in competency business margins is expected to offset this [5] - Shenwan Hongyuan anticipates a year-on-year expansion of approximately 2 percentage points in Non-GAAP operating profit margin to 4.7% for 2QFY26, with the education business margin at 4.1%, up 0.9 percentage points year-on-year [5]

Core Viewpoint - Fluence (FLNC.US) experienced a significant stock increase of 13.24% on Wednesday, with a total rise of up to 19% since the announcement of its Q4 earnings [1] Financial Performance - The Q4 performance of Fluence was mixed, but the company projects a 50% revenue growth for the fiscal year 2026 [1] - Despite a year-over-year decline of one-third in total new orders, Q4 showed a positive trend with a 21% year-over-year increase in new orders, marking a return to growth after three consecutive quarters of decline [1] - The gross margin exceeded expectations, and the preliminary guidance for fiscal year 2026 indicates a median of 12%, surpassing Wall Street's average expectation of 10.9% [1] Analyst Insights - Jefferies analyst Julian Dumoulin-Smith upgraded Fluence's rating from "Underperform" to "Neutral," raising the target price from $11 to $16 [1] - Dumoulin-Smith noted that the company's profit margins are improving and signs of recovery are finally visible [1] - He indicated that fiscal year 2025 will be challenging for Fluence, but the outlook for fiscal year 2026 appears increasingly attractive as the company nears resolution of AESC issues and initial signs of recovery in the U.S. market emerge [1] Market Outlook - Dumoulin-Smith expressed that the recovery in Fluence's core U.S. market is on track, with macro headwinds largely becoming a thing of the past [1] - The decision to upgrade the rating was based on continuous improvement signals from the end market [1]

Core Viewpoint - 康师傅控股's stock price has risen over 4%, reaching a new high of 11.86 HKD since July, with a cumulative increase of 10% over three trading days [1] Group 1: Stock Performance - The stock price of 康师傅控股 increased by 4.22% to 11.85 HKD, with a trading volume of 283 million HKD [1] - The recent rise in stock price is attributed to a report from Goldman Sachs following a non-deal roadshow with 康师傅's management [1] Group 2: Financial Outlook - 康师傅 is facing challenges in achieving its sales target for the fiscal year 2025, which was originally expected to be flat to low single-digit growth, primarily due to weak beverage business [1] - However, the company is still on track to meet its profit target, with expected double-digit growth in recurring net profit, driven by pricing base effects, favorable cost conditions, efficiency improvements, and strict promotional management [1] - For 2026, 康师傅's management emphasized a focus on improving profit margins while aiming to restore revenue growth and continue efficiency enhancement measures [1] Group 3: Procurement Strategy - The company typically locks in procurement for various raw materials for periods ranging from half a month to several months [1]

Core Viewpoint - 康师傅控股's stock price has risen over 4%, reaching a new high of 11.86 HKD since July, with a cumulative increase of 10% over three trading days [1] Group 1: Stock Performance - The stock price increased by 4.22% to 11.85 HKD, with a trading volume of 283 million HKD [1] Group 2: Company Outlook - Goldman Sachs reported that 康师傅 is facing challenges in achieving its sales target for fiscal year 2025, which was originally expected to be flat to low single-digit growth, primarily due to weak beverage business [1] - Despite sales challenges, 康师傅 is expected to meet its profit target, with recurring net profit projected to grow by double digits annually, driven by pricing base effects, favorable cost conditions, efficiency improvements, and strict promotional management [1] - For 2026, 康师傅's management reiterated a focus on improving profit margins while aiming to restore revenue growth and continue efficiency enhancement measures [1] - The company typically locks in procurement of various raw materials for periods ranging from half a month to several months [1]

Core Insights - The company reported better-than-expected performance for FY26Q1, with a revenue growth of 6.1% year-on-year, surpassing the previous guidance of 2%-5% [1] - The company anticipates a revenue growth of 9%-12% for FY26Q2 and maintains an annual growth target of 5%-10% [1] - The out-of-country business showed unexpected improvement, with a 1% growth in exam preparation and a 2% growth in study abroad consulting, indicating a recovery from previous pessimistic forecasts [1] Revenue and Growth Indicators - Deferred revenue increased by 10% year-on-year, and the renewal rate improved across all segments, suggesting robust growth [1] - The K12 business is expected to accelerate significantly in FY26Q2, with K9 growth around 20% and high school showing double-digit growth, validating the strategy of prioritizing product quality [2] - The active paid users in the OMO business reached 452,000, indicating potential for user retention and scalability [2] Shareholder Returns and Financial Health - The company announced a $190 million dividend and a $300 million buyback plan, totaling approximately $490 million, which represents over 130% of FY25 net profit [3] - Cash and cash equivalents stood at $5.03 billion as of FY26Q1, allowing for shareholder returns while maintaining strategic investments [3] - The combination of regular dividends and ongoing buybacks reflects a mature approach to shareholder returns, with a commitment to high payout ratios [3] Profitability and Cost Management - The Non-GAAP operating profit margin improved to 22.0%, driven by better resource utilization, operational leverage, and effective cost control [4] - The company expects further margin expansion in FY26Q2, with a focus on improving profitability in the core business [4] - The shift in the out-of-country business from being a drag on profits to reducing losses is a positive development [4] Earnings Forecast - The company maintains its Non-GAAP net profit forecasts for FY2026-2028 at $580 million, $630 million, and $690 million, respectively [4] - The current stock price corresponds to a PE ratio of 17, 15, and 14 for FY2026-2028, indicating a favorable valuation [4]

Core Viewpoint - The company's mid-year performance meets expectations, with revenue decline primarily due to the shift in sales model for joint products from distribution to distribution, leading to a decrease in factory prices. Profit growth is high, mainly due to reduced sales expenses from the sales model adjustment and improved operational efficiency from refined management. Looking ahead to the second half of the year, despite the expected impact on revenue from the sales model adjustment in the joint and tissue repair business, the spine and trauma segments are expected to maintain steady growth, with profit margins likely to continue improving year-on-year, and profit growth expected to outpace revenue growth. The annual profit is expected to meet the assessment targets of the restricted stock incentive plan [1][4][6]. Financial Performance - In the first half of 2025, the company achieved revenue of 741 million yuan, a year-on-year decrease of 1.28%; net profit attributable to shareholders was 142 million yuan, a year-on-year increase of 52.43%; and net profit excluding non-recurring items was 136 million yuan, a year-on-year increase of 51.98%. Basic earnings per share were 0.35 yuan. The company plans to distribute a cash dividend of 1.00 yuan (including tax) for every 10 shares, totaling approximately 39.73 million yuan [2][3]. Sales and Profitability - The company's gross profit margin for the first half of the year was 66.50% (+2.43 percentage points), and the sales expense ratio was 26.49% (-10.63 percentage points). The decrease in sales expenses was mainly due to optimized marketing and personnel structures, channel integration, and refined management of market expenses. The net profit margin was 19.52% (+6.71 percentage points), benefiting from the increase in gross margin and decrease in expense ratios. The net cash flow from operating activities was 186 million yuan (+28.66%), mainly due to reduced cash expenses [5][6]. International Expansion - The company achieved overseas revenue of 43.21 million yuan in the first half of the year, a year-on-year increase of 19%. The company is accelerating its international strategy, gradually improving its overseas divisions, concentrating resources on strategic markets (Indonesia, Brazil, Russia, Thailand, etc.), and establishing benchmark sales channels. It is also deepening localized operations in developed trade markets (Central Asia, Africa, etc.) and quickly entering untapped markets (Mexico, Saudi Arabia, Europe, etc.) [3][4]. Future Outlook - The company is expected to maintain steady growth in performance after the impact of centralized procurement clears. The centralized procurement in various segments of orthopedics has been implemented, with joint and trauma procurement renewals completed, and the company’s bid prices are expected to remain stable. The spine procurement renewal is anticipated to commence by the end of this year or early next year, with expected stable pricing based on previous results. The company is expected to achieve a net profit of no less than 290 million yuan, excluding stock payment expenses, meeting the targets of the restricted stock incentive plan [4][6]. Long-term Growth Potential - The orthopedic industry has good growth potential, and the company’s comprehensive product line is expected to leverage its advantages in branding, channels, and research and development to maintain its leading position in the industry. Revenue projections for 2025-2027 are 1.616 billion yuan, 1.890 billion yuan, and 2.213 billion yuan, representing year-on-year growth of 11.2%, 17.0%, and 17.1%, respectively. Net profit attributable to shareholders is projected to be 293 million yuan, 361 million yuan, and 429 million yuan, with year-on-year growth of 31.1%, 23.0%, and 18.8% [6][7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The report indicates that the company is at a turning point for profit margin improvement, with expectations for continued growth in sales and profitability across various product lines [12] - The company’s revenue and profit performance in the first half of 2025 met expectations, with a forecast for ongoing improvements in profit margins [5][13] Financial Summary - Total shares outstanding: 259.11 million [2] - Market price: 200.22 CNY [2] - Market capitalization: 51,878.28 million CNY [2] - Revenue projections for 2023A to 2027E show significant growth, with 2025E revenue expected to reach 18,382 million CNY, reflecting a year-over-year growth rate of 54% [4] - Net profit for 2023A is projected at 2,051 million CNY, with a decline expected in 2024A and 2025E, followed by recovery in subsequent years [4] Product Performance - The company’s revenue from robotic vacuum cleaners in Q2 2025 was 35 billion CNY, showing a 50% year-over-year increase, driven by domestic subsidies and market penetration in new regions [7] - The washing machine segment saw a remarkable revenue increase of 700% in Q2 2025 compared to Q1 2025, indicating strong market demand and successful product launches [9] - The company anticipates a reduction in losses for its washer-dryer integrated machines in the second half of 2025 as promotional efforts taper off [10] Profitability Analysis - The net profit margin for Q2 2025 was 9.2%, showing a year-over-year decline but an improvement from the previous quarter [11] - The report highlights that the company is expected to achieve profitability in the washing machine segment moving forward, with both domestic and international sales contributing positively [11]

Core Viewpoint - The company reported a strong recovery in its business segments for the first half of 2025, with significant growth in net income and EBITDA, driven by robust performance in the mid-market gaming sector [1][2]. Financial Performance - In H1 2025, the company achieved net revenue of $292 million, a year-on-year increase of 19.9% [1] - EBITDA, excluding the impact of the Vladivostok project impairment, was $200 million, reflecting a year-on-year growth of 38.5% [1] - The overall gross gaming revenue (GGR) reached $332 million, up 17.2% year-on-year [1] - The mid-market gaming table GGR was $162 million, increasing by 24.0% year-on-year [1] - The company’s comprehensive gross margin improved to 80.7%, a 1.8% increase year-on-year, primarily due to faster growth in the mid-market gaming table segment [2] Business Segment Analysis - The mid-market gaming table segment showed a gross margin of 91.9%, up 0.3 percentage points year-on-year [2] - High-end VIP business GGR recovered to 138.8% of the same period in 2019, with a year-on-year increase of 89.0% [1][2] - The company’s administrative expenses were reduced by 35.6% year-on-year, contributing to improved EBITDA and net profit margins [2] Competitive Advantage - The company holds exclusive operating rights in the Phnom Penh area until 2045, enhancing its competitive position in Southeast Asia [3] - Cambodia's gaming tax rates are competitive, at 7% for mid-market GGR and 4% for non-mid-market GGR, allowing the company to offer attractive commission policies to high-end clients [3] Growth Outlook - The company is expected to maintain steady growth in the medium to long term, supported by ongoing foreign direct investment and increased tourism demand [3] - Projections for EBITDA from 2025 to 2027 are $401 million, $445 million, and $487 million, respectively [3] - The company is rated as a strong buy due to its exclusive operating rights and sustainable growth potential, with a 2025 EV/EBITDA of 7.4x and a P/E of 11.4x [3]